{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:08:41Z","timestamp":1793581721147,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The Norwegian Multiple Sclerosis Society"},{"DOI":"10.13039\/100009471","name":"Stiftelsen Dam","doi-asserted-by":"publisher","award":["2021\/FO347349"],"award-info":[{"award-number":["2021\/FO347349"]}],"id":[{"id":"10.13039\/100009471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["288164"],"award-info":[{"award-number":["288164"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Torbj\u00f8rg Hauges fund"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Head-to-head comparisons of high-efficacy therapies for relapsing\u2013remitting multiple sclerosis (RRMS) are lacking. We conducted a target trial emulation to compare the long-term effectiveness of rituximab and cladribine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We estimated the effect of initiating treatment with rituximab versus cladribine using observational data from the Norwegian MS Registry and Biobank at two university hospitals with different treatment strategies. Cumulative incidence and risk differences (RDs) were estimated using weighted Kaplan-Meier estimators, adjusting for baseline covariates. The primary outcome was magnetic resonance imaging (MRI) disease activity, with secondary outcomes including relapses and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study included 285 patients, 159 receiving rituximab and 126 cladribine, with a median follow-up of 4.5 years (interquartile range (IQR): 4.2\u20134.7). The 4-year risk of new MRI disease activity was 17% (95% confidence interval (CI): 11\u201323) for rituximab-treated patients and 57% (95% CI: 44\u201366) for cladribine-treated patients, yielding an RD of 40 percentage-points (95% CI: 28\u201350). The 4-year RD for relapse was 12 percentage-points (95% CI: 4\u201319). The incidence of hospitalizations related to potential adverse events was 6.0 per 100 person-years for rituximab and 4 per 100 person-years for cladribine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings suggest that rituximab has superior effectiveness compared to cladribine during a median follow-up of 4.5 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585251342727","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:25:45Z","timestamp":1748233545000},"page":"975-984","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness of rituximab and cladribine in relapsing\u2013remitting multiple sclerosis: A target trial emulation"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2200-1525","authenticated-orcid":false,"given":"Brit Ellen","family":"R\u00f8d","sequence":"first","affiliation":[{"name":"Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"The Norwegian Multiple Sclerosis Registry and Biobank, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar A","family":"H\u00f8gest\u00f8l","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Psychology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[{"name":"Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Bj\u00f8rnevik","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology and Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Michael","family":"Gran","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-2644","authenticated-orcid":false,"given":"Mathias H","family":"\u00d8ver\u00e5s","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marton","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0980-510X","authenticated-orcid":false,"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[{"name":"Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[{"name":"Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"The Norwegian Multiple Sclerosis Registry and Biobank, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro O","family":"Nygaard","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2125"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00209-5"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327612"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5109"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.15.1361"},{"issue":"1","key":"e_1_3_3_11_2","article-title":"Safety and efficacy of rituximab as first\u2014and second line treatment in multiple sclerosis\u2014a cohort study","volume":"7","author":"Torgauten HM","year":"2021","unstructured":"Torgauten HM, Myhr KM, Wergeland S, et al. Safety and efficacy of rituximab as first\u2014and second line treatment in multiple sclerosis\u2014a cohort study. Mult Scler J Exp Transl Clin 2021; 7(1): 2055217320973049.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_3_13_2","volume-title":"Causal Inference: What If","author":"Hern\u00e1n M","year":"2020","unstructured":"Hern\u00e1n M, Robins J. Causal Inference: What If. Boca Raton: CRC Press, 2020."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.1961"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6775-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617753365"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.0826"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211012227"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103812"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241267211"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517713668"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"e_1_3_3_23_2","first-page":"104","article-title":"Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis","volume":"91","author":"Benkert P","year":"2024","unstructured":"Benkert P, Maleska Maceski A, Schaedelin S, et al. Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under b-cell depleting treatment in multiple sclerosis. Ann Neurol 2024; 91: 104\u2013115.","journal-title":"Ann Neurol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0688"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012753"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105770"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200164"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585251342727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585251342727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585251342727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:18:35Z","timestamp":1777695515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585251342727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/13524585251342727"],"URL":"https:\/\/doi.org\/10.1177\/13524585251342727","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.10.24318773","asserted-by":"object"}]},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}